基于 8 个新的且经过验证的焦亡相关基因的弥漫性大 B 细胞淋巴瘤风险预测模型。
A Novel and Validated 8-Pyroptosis-Related Genes Based Risk Prediction Model for Diffuse Large B Cell Lymphoma.
机构信息
Department of Laboratory Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
Department of Biochemistry and Molecular Cell Biology, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
出版信息
Biomolecules. 2022 Dec 8;12(12):1835. doi: 10.3390/biom12121835.
BACKGROUND
Diffuse large B-cell lymphoma (DLBCL), the most common type of Non-Hodgkin's Lymphoma (NHL), has a lethal nature. Thus, the establishment of a novel model to predict the prognosis of DLBCL and guide its therapy is an urgency. Meanwhile, pyroptosis is engaged in the progression of DLBCL with further investigations required to reveal the underlying mechanism.
METHODS
LASSO regression was conducted to establish a risk model based on those PRGs. External datasets, RT-qPCR and IHC images from The Human Protein Alta (HPA) database were utilized to validate the model. ssGSEA was utilized to estimate the score of immune components in DLBCL.
RESULTS
A model based on 8 PRGs was established to generate a risk score. Validation of the model confirmed its robust performance. The risk score was associated with advanced clinical stages and shorter overall survivals. Two novel second-line chemotherapies were found to be potential treatments for high-risk patients. The risk score was also found to be correlated with immune components in DLBCL.
CONCLUSION
This novel model can be utilized in clinical practices to predict the prognosis of DLBCL and guide the treatment of patients at high risk, providing an overview of immune regulatory program via pyroptosis in DLBCL.
背景
弥漫性大 B 细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤（NHL）类型，具有致命性。因此，建立一种新的模型来预测 DLBCL 的预后并指导其治疗是当务之急。同时，细胞焦亡参与了 DLBCL 的进展，需要进一步研究来揭示其潜在机制。
方法
基于这些 PRGs，使用 LASSO 回归建立风险模型。利用外部数据集、RT-qPCR 和来自人类蛋白质图谱（HPA）数据库的 IHC 图像对模型进行验证。ssGSEA 用于估计 DLBCL 中免疫成分的评分。
结果
建立了一个基于 8 个 PRGs 的模型来生成风险评分。模型的验证证实了其稳健的性能。风险评分与较晚的临床分期和较短的总生存期相关。发现两种新型二线化疗可能是高危患者的潜在治疗方法。风险评分还与 DLBCL 中的免疫成分相关。
结论
该新模型可用于临床实践，以预测 DLBCL 的预后，并指导高危患者的治疗，通过细胞焦亡提供对 DLBCL 中免疫调节程序的概述。
Zotero 插件